¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ yfnqu4Cn  
_}EGk4E  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© `BmAu[(e&  
O+@"l$;N  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Gyw@+(l  
SVpvx`&kT  
1.Co-stimulators (or co-stimulating molecules) Y<#WC#3=  
nMNAn}~*M  
2.NK-kB !r,ZyJU  
7,d^?.~S  
3.Immunoglobulin superfamily ]m{;yOQdsC  
.1XZ9M  
4.antigen-presenting cell (APC) 4~53%=+  
DzkE*vR  
5.death domain Vrf2%$g  
KM*sLC#  
6.CCR and CXCR A=o p R  
wciYv,  
7.Lectin (or mitogen) U SXz  
?C(Z\"IX  
8.Clusters of differentiation, CD) dJ"3F(X  
l!lt gj  
9.B7 family !bFa\6]q  
pM9Hav@iWU  
10.Cytotoxic T lymphocyte, CTL) w1F7gd  
NIrK+uC.d  
11.IL-15 and IL-15 receptor (IL-15R) !T@>Ld:  
MeW8aL r  
12.MHC restriction Sdz!J 1  
*YZ' Uy?  
13.Affinity-chromatography ez%RWck  
BP6;dF5 E  
14.Cyctosprin A, CsA #.?DsK_:@  
Zk$AAjC&  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) M6vW}APH[n  
g-U'{I5F  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© pOS:/~I3  
t(VG#}  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 zh2$U dZ|M  
3M 8P%  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Y=sRVypJ  
Na=9 ju  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ I >k3X~cG  
SE)_5|k*  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© .q i$X!0  
D Km`  
ÃâÒßѧרҵ£º s@OCj0'l  
aj51%wKMb:  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 9G` 2t~%  
p<?~~7V  
Ïû»¯ÄÚ¿Æ£º YYr &Jc j  
n9]^v-]K  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ :k6|-A2  
gF^l`1f"  
ѪҺ²¡Ñ§×¨Òµ£º ~mOGNf?f  
gZuk(  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»